PF-2341066 shows inhibition of Met phosphorylation in mIMCD3 mouse of MDCK canine epithelial cells with an IC50 of 5 nM and 20 nM, respectively, as well as NCI-H69 and HOP92 cells, with an IC50 of 13 nM and 16 nM, respectively. PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion varient of the ALK RTK expressed by the KARPAS299 human anaplastic large-cell lymphoma (ALCL) cell line. PF-2341066 supresses human GTL-16 gastric carcinoma cell growth with an IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with an IC5050 of 30 nM. A Met inhibitor effective against various cell lines Crizotinib has been used: · to investigate its effects on hepatocyte growth factor receptor (c-Met) expression, proliferation and apoptosis · to block neurotrophic tyrosine kinase receptor type 1 (NTRK1) activity in epithelial cells · to restore sensitivity to erlotinib PF-2341066 shows inhibition of Met phosphorylation in mIMCD3 mouse of MDCK canine epithelial cells with an IC50 of 5 nM and 20 nM, respectively, as well as NCI-H69 and HOP92 cells, with an IC50 of 13 nM and 16 nM, respectively. PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion varient of the ALK RTK expressed by the KARPAS299 human anaplastic large-cell lymphoma (ALCL) cell line. PF-2341066 supresses human GTL-16 gastric carcinoma cell growth with an IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with an IC5050 of 30 nM. A Met inhibitor effective against various cell lines Crizotinib has been used: · to investigate its effects on hepatocyte growth factor receptor (c-Met) expression, proliferation and apoptosis · to block neurotrophic tyrosine kinase receptor type 1 (NTRK1) activity in epithelial cells · to restore sensitivity to erlotinib